We are live on ! Find out more
DFTX

Definium Therapeutics

Delisted

DFTX was delisted on the 24th of June, 2026.

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 62.9%
Negative

Neutral
Business Wire
1 day ago
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de.
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Positive
Zacks Investment Research
1 day ago
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Neutral
Business Wire
2 days ago
Definium Therapeutics, Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. I.
Definium Therapeutics, Inc. Announces Proposed Public Offering
Positive
Proactive Investors
2 days ago
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical company reported positive topline results from its Phase 3 Emerge study evaluating DT120, an orally disintegrating formulation of lysergide (LSD), in adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled trial met its primary endpoint and all key secondary efficacy endpoints.
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Neutral
Seeking Alpha
2 days ago
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Positive
Investors Business Daily
2 days ago
This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.
Definium Therapeutics skyrocketed Monday after its psychedelics-based depression treatment scored a "best-case" win in final-phase testing.
This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.
Positive
Benzinga
2 days ago
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment
Definium Therapeutics Inc. (NASDAQ:DFTX) shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder—with the trial meeting its primary and all key secondary efficacy endpoints.
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment
Neutral
Business Wire
2 days ago
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD). Emerge met i.
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Neutral
Business Wire
3 days ago
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 µg in adults with.
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Neutral
Business Wire
9 days ago
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026.
Definium Therapeutics Announces New Employee Inducement Grants